206 related articles for article (PubMed ID: 37572133)
1. Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor induced myasthenia gravis, myocarditis and myositis: a case series.
Weaver JM; Dodd K; Knight T; Chaudhri M; Khera R; Lilleker JB; Roberts M; Lorigan P; Cooksley T
Support Care Cancer; 2023 Aug; 31(9):518. PubMed ID: 37572133
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Immune Checkpoint Inhibitor-Induced Myasthenia Gravis Using the US Food and Drug Administration Adverse Event Reporting System.
Niimura T; Zamami Y; Miyata K; Mikami T; Asada M; Fukushima K; Yoshino M; Mitsuboshi S; Okada N; Hamano H; Sakurada T; Matsuoka-Ando R; Aizawa F; Yagi K; Goda M; Chuma M; Koyama T; Izawa-Ishizawa Y; Yanagawa H; Fujino H; Yamanishi Y; Ishizawa K
J Clin Pharmacol; 2023 Apr; 63(4):473-479. PubMed ID: 36453166
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors.
Aldrich J; Pundole X; Tummala S; Palaskas N; Andersen CR; Shoukier M; Abdel-Wahab N; Deswal A; Suarez-Almazor ME
Arthritis Rheumatol; 2021 May; 73(5):866-874. PubMed ID: 33258544
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases.
Pathak R; Katel A; Massarelli E; Villaflor VM; Sun V; Salgia R
Oncologist; 2021 Dec; 26(12):1052-1061. PubMed ID: 34378270
[TBL] [Abstract][Full Text] [Related]
5. [Clinical features of immune checkpoint inhibitor-related myositis in patients with urological cancer].
Ying YC; Tang Q; Yang KW; Mi Y; Fan Y; Yu W; Song Y; He ZS; Zhou LQ; Li XS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):644-651. PubMed ID: 35950386
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.
Suzuki S; Ishikawa N; Konoeda F; Seki N; Fukushima S; Takahashi K; Uhara H; Hasegawa Y; Inomata S; Otani Y; Yokota K; Hirose T; Tanaka R; Suzuki N; Matsui M
Neurology; 2017 Sep; 89(11):1127-1134. PubMed ID: 28821685
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome.
Lipe DN; Galvis-Carvajal E; Rajha E; Wechsler AH; Gaeta S
Am J Emerg Med; 2021 Aug; 46():51-55. PubMed ID: 33721590
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitor-induced myocarditis, myositis, myasthenia gravis and transaminitis: a case series and review.
Wai Siu DH; O'Neill RS; Harris CA; Wang J; Ardolino L; Downton T; Tong M; Hong JH; Chin V; Clingan PR; Aghmesheh M; Soudy H
Immunotherapy; 2022 May; 14(7):511-520. PubMed ID: 35321560
[TBL] [Abstract][Full Text] [Related]
9. A case report and literature review on respiratory failure with immune checkpoint inhibitors: a life-threatening adverse event.
Lin X; Guan W; Li B; Deng H; Chen Y; Yang Y; Qiu G; Xie X; Zhou C
Immunopharmacol Immunotoxicol; 2023 Dec; 45(6):780-787. PubMed ID: 37339370
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics, treatment and outcome of nivolumab-induced myasthenia gravis.
Wang C; Zeng H; Fang W; Song L
Invest New Drugs; 2023 Apr; 41(2):333-339. PubMed ID: 36988830
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitor-induced Myositis.
Jayan A; Mammen AL; Suarez-Almazor ME
Rheum Dis Clin North Am; 2024 May; 50(2):281-290. PubMed ID: 38670726
[TBL] [Abstract][Full Text] [Related]
12. Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report.
Cham J; Ng D; Nicholson L
J Med Case Rep; 2021 May; 15(1):278. PubMed ID: 34053457
[TBL] [Abstract][Full Text] [Related]
13. Myasthenia gravis, myositis and myocarditis: a fatal triad of immune-related adverse effect of immune checkpoint inhibitor treatment.
Soman B; Dias MC; Rizvi SAJ; Kardos A
BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36593626
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitors induced side effects of the peripheral nervous system.
Hundsberger T; Schreiner B; Roth P
Curr Opin Neurol; 2023 Oct; 36(5):427-431. PubMed ID: 37639489
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitor-Associated Myositis: A Distinct Form of Inflammatory Myopathy.
Saygin D; Ghosh N; Reid P
J Clin Rheumatol; 2022 Oct; 28(7):367-373. PubMed ID: 35696731
[TBL] [Abstract][Full Text] [Related]
16. Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature.
Boutros A; Bottini A; Rossi G; Tanda ET; Spagnolo F; Barletta G; Croce E; Fava P; Parisi A; De Rosa F; Palla M; Marconcini R; Ferrari M; Grandis M; Spallarossa P; Sarocchi M; Arboscello E; Del Mastro L; Lambertini M; Pronzato P; Genova C
ESMO Open; 2023 Feb; 8(1):100791. PubMed ID: 36791639
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
Valenti-Azcarate R; Esparragosa Vazquez I; Toledano Illan C; Idoate Gastearena MA; Gállego Pérez-Larraya J
Neuromuscul Disord; 2020 Jan; 30(1):67-69. PubMed ID: 31839404
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitor-mediated myasthenia gravis with focal subclinical myocarditis progressing to symptomatic cardiac disease.
Leaver PJ; Jang HS; Vernon ST; Fernando SL
BMJ Case Rep; 2020 May; 13(5):. PubMed ID: 32404371
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibition-Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade.
Nelke C; Pawlitzki M; Kerkhoff R; Schroeter CB; Aktas O; Neuen-Jacob E; Polzin A; Meuth SG; Ruck T
Neurol Neuroimmunol Neuroinflamm; 2024 Jan; 11(1):. PubMed ID: 37884388
[TBL] [Abstract][Full Text] [Related]
20. Consider Myocarditis When Patients Treated with Immune Checkpoint Inhibitors Present with Ocular Symptoms.
Rhee JY; Torun N; Neilan TG; Guidon AC
Oncologist; 2022 May; 27(5):e402-e405. PubMed ID: 35348772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
